Capitalizing on Late-Stage Clinical Success, Strengthening Target & Modality Differentiation & Translating Complement into Ocular, CNS, Oncology & Autoimmune Indications
The 10th Complement-Based Drug Development Summit returns at a pivotal moment as the field shifts from validating complement biology to maximizing its clinical and commercial potential. As pipelines expand beyond C3 and C5 and competition intensifies, developers are focused on identifying the right targets, modalities, and indications to drive differentiation and patient impact. Recent milestones, including
Regeneron's cemdisiran advancing through FDA and EMA review and Biogen's acquisition of Apellis, highlight the growing momentum and investment shaping the next era of complement therapeutics.
As the industry's only dedicated forum uniting complement leaders, this meeting will address the strategic and scientific priorities shaping the next generation of complement therapeutics, including:
- Advancing clinical success through biomarker innovation, improved target engagement strategies, robust trial design, and smarter indication selection to de-risk development
- Benchmarking next-generation modalities across siRNA, gene therapy, biologics, and novel delivery technologies to improve durability, efficacy, safety, and patient outcomes
- Expanding beyond C3 and C5 to evaluate intracellular complement biology, emerging targets, novel mechanisms, and combination approaches shaping the next generation of complement therapeutics
- Unlocking growth beyond renal disease by assessing the translational and clinical opportunity across neurodegenerative, ocular, autoimmune, haematological, oncology, and acute indications
It was great to hear about the current status of clinical-stage programs in the field, new and exciting preclinical research, and thought-provoking discussion from the audience!
Principal Scientist, Sanofi
Good mix of academic scientists and drug developers with preclinical, clinical and regulatory expertise.
Chief Scientific Officer, Beacon Therapeutics
I enjoyed networking with colleagues and the deep complement discussions. The program was also well balanced.
Director, Apellis Pharmaceuticals
Explore The New Full Event Guide
- 22+ Expert Speakers Discussing CNS, Ocular, Renal, Oncology & Autoimmune Programs
- 3 Days of End-to-End Learnings to Support your Pipeline Progression
- 2 Discussion-Led Workshops lead by Industry & Academic Pioneers
- 1 Scientific Poster Session to Share your Research with the Community
- Content Across siRNA, Gene Therapy, Biologics & Small Molecules
2025 World-Class Speaker Faculty Included:
Official Partners
Attending Companies Include:
Explore Related Events
Explore the Agenda
Discover three days of content spanning novel targets, modalities and indications, powering your complement-based pipeline.
Partner With Us
Elevate your brand and showcase your solutions to a world-class audience of complement drug developers.
Join Biopharma Experts
Uniting large pharma experts, C-Level biotech leaders and KOLs, this forum is designed to foster vital industry connections.